Loading
A phase 3 trial of Odronextamab, Ifosfamide, Carboplatin in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT06230224 by Regeneron Pharmaceuticals, with 216 participants enrolled, started 2024-02-15 and due to reach its primary completion in 2028-05-29. Interventions recorded: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab. Conditions listed: B-Cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.
Shares Ifosfamide, Etoposide, Rituximab, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Ifosfamide, Etoposide, Rituximab, Non-Hodgkin lymphoma (all types).
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Ifosfamide, Dexamethasone, Etoposide, Non-Hodgkin lymphoma (all types).